Symbols

RGNX

Regenxbio·NASDAQ

--(--)

RGNX fundamentals

RGNX Q4 2025 Earnings

Regenxbio (RGNX) released its earnings on Mar 5, 2026: revenue was 30.34M (YoY +43.00%), missed estimates; EPS was -1.3 (YoY -28.71%), missed estimates.

Revenue / YoY

30.34M

+43.00%

EPS / YoY

-1.3

-28.71%

Report date

Mar 5, 2026

RGNX Earnings Call Summary for Q4,2025

RGX-202 Pivotal Progress: 18-month Phase I/II NSAA data shows 7.4% improvement vs. cTAP; 12-month pivotal data expected Q4 2026. FDA pre-BLA meeting mid-2026.
Retinal Pipeline Expansion: AbbVie partnership advances wet AMD and DR programs; NAVIGATE trial for DR to begin Q2 2026 with $100M milestone.
Financial Strength: $241M cash balance supports operations into 2027; 2025 revenue $170M driven by AbbVie collaboration and gene therapy royalties.
Safety & Regulatory Confidence: RGX-202 safety profile (0 SAEs) and functional data differentiation position for accelerated approval. MPS programs addressing rare tumor case with enhanced monitoring.

Earnings

EPS

Revenue

Revenue & Expenses

RGNX has released its 2025 Q4 earnings report, with revenue of 30.34M, reflecting a YoY change of 43.00%, and net profit of -67.15M, showing a YoY change of -31.19%. The Sankey diagram below clearly presents RGNX's revenue sources and cost distribution.

Key Indicators

Regenxbio (RGNX) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Regenxbio (RGNX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Regenxbio (RGNX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Regenxbio (RGNX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown